Smartphone cameras could play an important role in the diagnosis of AFib, according to new findings published in JAMA Network Open.

Oral anticoagulation medication can help minimize bleeding complications among AFib patients undergoing transcatheter aortic valve replacement (TAVR), according to new research out of Europe.

A significant number of life-threatening complications in pregnant women with heart disease could be prevented altogether, according to new findings published by the Journal of the American College of Cardiology.

A patient’s e-cigarette interfered with their implantable cardioverter-defibrillator (ICD) and prevented the device from properly functioning, according to a new analysis published in HeartRhythm Case Reports.

On a biweekly basis, researchers and physicians at the Feinstein Institutes for Medical Research and North Shore University Hospital in New York gather to watch footage of patient resuscitations.

Nearly a quarter of older patients with atrial fibrillation receive inappropriately dosed direct-acting oral anticoagulants, according to an analysis of the ongoing SAGE-AF study.

A new analysis of the CASTLE-AF trial has found that catheter ablation for AFib remains effective in a much larger group of heart failure patients, cementing evidence first presented in early 2018.

A small-scale study published in Circulation March 3 has revealed a potential new culprit behind sudden cardiac death in patients with arrhythmogenic right ventricular cardiomyopathy: integrin β1D.

Researchers at Imperial College London have developed a new type of sensor that can track vital signs in both humans and animals, suggesting the ever-growing wearables trend is expanding to include pets and livestock.

Pulsed field ablation technology has been used to treat atrial fibrillation for the first time in the U.S.

A study published Feb. 25 in Circulation suggests wearables are useful for detecting CV abnormalities like atrial fibrillation, but there’s still a long way to go before they can be trusted for clinical management.

A secondary analysis of the AUGUSTUS trial confirms earlier findings that treating heart patients with the anticoagulant apixaban results in less major bleeding, hospitalization and death than warfarin, a standard-of-care blood thinner.